Humacyte (NASDAQ:HUMA) Earns Buy Rating from D. Boral Capital

Humacyte (NASDAQ:HUMA)‘s stock had its “buy” rating restated by investment analysts at D. Boral Capital in a note issued to investors on Friday,Benzinga reports. They currently have a $25.00 price objective on the stock.

Other equities analysts have also issued reports about the stock. UBS Group reaffirmed a “buy” rating on shares of Humacyte in a research report on Monday, December 1st. Benchmark cut their target price on Humacyte from $11.00 to $10.00 and set a “buy” rating on the stock in a research note on Wednesday, January 21st. BTIG Research decreased their price objective on Humacyte from $6.00 to $3.00 and set a “buy” rating for the company in a report on Friday. HC Wainwright reissued a “buy” rating and issued a $3.00 price objective on shares of Humacyte in a research report on Monday, December 1st. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Humacyte in a research note on Monday, December 29th. Seven investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, Humacyte presently has an average rating of “Moderate Buy” and an average target price of $7.71.

Humacyte Stock Performance

Humacyte stock opened at $0.68 on Friday. The company has a debt-to-equity ratio of 2.97, a current ratio of 1.62 and a quick ratio of 0.90. Humacyte has a 1-year low of $0.67 and a 1-year high of $2.93. The firm has a market capitalization of $126.52 million, a P/E ratio of -3.38 and a beta of 1.89. The company’s 50-day moving average is $1.04 and its 200 day moving average is $1.28.

Humacyte (NASDAQ:HUMA) last announced its earnings results on Friday, March 27th. The company reported ($0.13) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.13). The business had revenue of $0.47 million for the quarter, compared to analysts’ expectations of $1.35 million. Research analysts forecast that Humacyte will post -1.27 EPS for the current year.

Hedge Funds Weigh In On Humacyte

Several hedge funds have recently made changes to their positions in HUMA. Aristides Capital LLC acquired a new stake in Humacyte during the 4th quarter worth about $156,000. Fisher Asset Management LLC purchased a new position in shares of Humacyte in the fourth quarter worth about $47,000. R Squared Ltd acquired a new stake in shares of Humacyte during the fourth quarter worth about $25,000. United Asset Strategies Inc. lifted its holdings in shares of Humacyte by 13.5% during the fourth quarter. United Asset Strategies Inc. now owns 209,608 shares of the company’s stock worth $201,000 after purchasing an additional 25,000 shares during the period. Finally, SG Americas Securities LLC boosted its position in Humacyte by 50.3% in the fourth quarter. SG Americas Securities LLC now owns 34,075 shares of the company’s stock valued at $33,000 after buying an additional 11,411 shares during the last quarter. 44.71% of the stock is owned by institutional investors and hedge funds.

Key Stories Impacting Humacyte

Here are the key news stories impacting Humacyte this week:

• Positive Sentiment: D. Boral Capital reaffirmed a “buy” rating and set an outsized $25.00 price target, signaling strong upside expectations from that firm. Benzinga
• Positive Sentiment: Humacyte named Rick McElheny SVP of Business Development to expand collaborations and commercialization efforts—management hire aimed at accelerating partnerships that could drive future revenue. GlobeNewswire: Appointment
• Neutral Sentiment: Full earnings call transcript is available for investors wanting management commentary and Q&A that could clarify outlook and commercial plans. Earnings Call Transcript
• Negative Sentiment: Q4 results: GAAP loss of ($0.13) per share met consensus, but revenue came in at roughly $0.47–0.5M versus analyst expectations near $1.35M (and full‑year sales only $2.0M). The revenue shortfall and low near-term sales reduce near-term visibility and likely pressured the stock. MarketBeat: Earnings Press Release Zacks
• Negative Sentiment: BTIG reduced its price target from $6.00 to $3.00 (still a “buy”), signaling a more cautious near-term outlook from another sell-side firm and lowering consensus upside. Benzinga

About Humacyte

Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company’s proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient’s own tissue. Humacyte’s primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.

The company’s lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.